- Home
- PTGX vs FSK Comparison
PTGX vs FSK Comparison
Compare PTGX & FSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PTGX | FSK |
|---|---|---|
| Founded | 2006 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.2B |
| IPO Year | 2016 | 2008 |
Fundamental Metrics
Financial Performance| Metric | PTGX | FSK |
|---|---|---|
| Price | $92.39 | $10.74 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 8 |
| Target Price | ★ $100.17 | $14.63 |
| AVG Volume (30 Days) | 489.3K | ★ 4.4M |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 18.41% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | $711.26 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $274.25 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.60 | $10.28 |
| 52 Week High | $96.54 | $22.85 |
Technical Indicators
Market Signals| Indicator | PTGX | FSK |
|---|---|---|
| Relative Strength Index (RSI) | 60.15 | 23.08 |
| Support Level | $76.63 | N/A |
| Resistance Level | $92.05 | $16.05 |
| Average True Range (ATR) | 3.87 | 0.48 |
| MACD | 0.79 | -0.17 |
| Stochastic Oscillator | 80.77 | 12.99 |
Price Performance
Historical ComparisonAbout PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
About FSK FS KKR Capital Corp.
FS KKR Capital Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation. The company's portfolio is comprised of investments in senior secured loans and second lien secured loans of private middle market U.S. companies and, to a lesser extent, subordinated loans and certain asset-based financing loans of private U.S. companies.